Functional activity of bone marrow progenitor cells in patients with chronic myeloid leukemia related to individual response to therapy

  • M. V. Diachenko Centre for Molecular and Cell Research of the National University of Kyiv-Mohyla Academy
  • I. Z. Borbulyak Centre for Molecular and Cell Research of the National University of Kyiv-Mohyla Academy
  • D. I. Bilko Centre for Molecular and Cell Research of the National University of Kyiv-Mohyla Academy
  • T. P. Perekhrestenko Institute of Haemotology and Transfusiology NAMS of Ukraine
  • N. M. Tretyak Institute of Haemotology and Transfusiology NAMS of Ukraine
  • I. S. Dyagil Scientific Centre of the Radiation Medicine NAMS of Ukraine
  • N. M. Bilko Centre for Molecular and Cell Research of the National University of Kyiv-Mohyla Academy

Abstract

The paper presents an effective method of the monitoring of individual response of the patients with chronic myeloid leukemia (CML) to the therapy with tyrosine kinase inhibitors (TKi). The growth patterns analysis of hematopoietic cells from CML patients showed that functional activity of bone marrow progenitor cells of the patients with complete response to TKi therapy was significantly lower (p < 0.05) in comparison with the colony-forming efficiency of bone marrow sampled from patients with a resistance to the therapy. The correlations were revealed between numbers of colony-forming units and the percentage of Ph+ cells in the bone marrow. This correlation was positive for the group of patients who were alternatively treated with the hydroxyurea and negative for the group of individuals with the resistance to TKi therapy.

References

Дягиль И. С. Субоптимальный ответ при лечении иматинибом ХМЛ как критерий риска развития резистентности // Укр. журнал гематології та трансфузіології. – 2009. – № 4 (9). – С. 27–29.

Hughes T. Clinical strategies to achieve an early and successful response to tyrosine kinase inhibitor therapy / T. Hughes, A. Hochhaus // Semin Hematol. – 2009. – Vol. 46. – P. 111–115. doi: 10.1053/j.seminhematol.2009.01.008

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity / A. S. Corbin, A. Agarwal, M. Loriaux et al. // J. of Clin. Inv. – 2011. – Vol. 121. – N 1. – P. 396–409. doi: 10.1172/JCI35721

Leber B. CML biology for the clinician in 2011: Six impossible things to believe before breakfast on the way to cure // Curr. Oncol. – 2011. – Vol. 18, N 4. – P. 185–190.

doi: 10.3747/co.v18i4.652

Philadelphia chromosome (Ph1)-negative chronic myelogenous leukemia (CML): A clonal disease with origin in a multipotent stem cell / P. J. Fialkow, R. J. Jacobson, J. W. Singer et al. // Blood. – 1980. – Vol. 56, N 1. – P. 70–73.

Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance / W. W. Zhang, J. E. Cortes, H. Yao et al. // J. Clin. Oncol. – 2009. – Vol. 27, N 22. – P. 3642–3649. doi: 10.1200/JCO.2008.19.4076

Published
2012-07-14
How to Cite
Diachenko, M. V., Borbulyak, I. Z., Bilko, D. I., Perekhrestenko, T. P., Tretyak, N. M., Dyagil, I. S., & Bilko, N. M. (2012). Functional activity of bone marrow progenitor cells in patients with chronic myeloid leukemia related to individual response to therapy. Regulatory Mechanisms in Biosystems, 3(2), 26-31. https://doi.org/10.15421/021228